Patterns of failure with 18F-DCFPyL PSMA-PET/CT in the post-prostatectomy setting: A regional cohort analysis

• Published in: Canadian Urological Association journal 2024-10, Vol.19 (2)
• Main Authors: Sigurdson, Samantha, al Salman, Khalid, Mesci, Aruz, Dayes, Ian, Quan, Kimmen, Goldberg, Mira, Schnarr, Kara, Shayegan, Bobby, Bauman, Glenn, Zukotynski, Katherine, Tsakiridis, Theos, Lukka, Himu
• Format: Article
• Language: English
• ISSN: 1911-6470; 1920-1214
• DOI: 10.5489/cuaj.8859

Introduction: This study aimed to assess the detection rate of prostate cancer recurrence by prostate-specific member antigen positron emission tomography/computed tomography (PSMA-PET/CT) with 18F-DCFPyL in patients with residual disease or biochemical recurrence (BCR), and its association with surgical pathology and prostate-specific antigen (PSA) kinetics. Methods: Men from South Central Ontario enrolled in the PSMA Registry for Recurrent Prostate cancer (PREP) between April 2019 and December 2021 after radical prostatectomy (RP) and who had 1) pathologic stage N1 or persistent elevated PSA; or 2) BCR (PSA >0.10 ng/mL) where initial postoperative PSA was undetectable were included. Results: A total of 169 men (median age 68 years; interquartile range [IQR] 62–71) with complete data met the above criteria. The median PSA was 0.27 ng/mL (IQR 0.16–0.85) prior to PSMA-PET. Overall positivity rate 59%; when PSA was